Founded in 2017 as a spin-off from Graz University of Technology, Austria-based VALANX Biotech engineers site-specific protein conjugations through its proprietary GoldenSite platform. The technology enables precise, reproducible attachment of therapeutic payloads to antibodies, aiming to widen the therapeutic window of antibody-drug conjugates (ADCs). VALANX’s lead program, VLX-ADC-001, targets the LIV-1 protein frequently expressed in metastatic triple-negative breast cancer, a tumor type with limited treatment options. The company intends to complete candidate selection for VLX-ADC-001 by June 2026 and to bring GoldenSite to GMP readiness for future clinical work and partnerships. Beyond the lead asset, VALANX plans to apply GoldenSite to additional ADC and protein-conjugate programs and to seek collaborations with other ADC developers. The most recent €3 million financing strengthens its balance sheet for preclinical studies, manufacturing scale-up, and business development activities. Key backers include strategic investor FUJIFILM Corporation, oncology-focused Foundation Fournier-Majoie, and repeat supporters such as xista science ventures, Tecnet Equity, and SOSV.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2026